Sep 29, 2020
Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital Nasdaq:AXSM Non-dilutive dedicated capital extends money runway into at the very least 2024 Facility strengthens steadiness sheet by way of anticipated business launches of Axsome’s two lead CNS product candidates NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical firm growing novel therapies for the administration of central nervous system (CNS) pro...
